Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657891 · ClinicalTrials.gov registry record · Phase 4
The Effect of Xolair (Omalizumab) on Allergy Blood Cells
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
NCT00657891 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 49 participants.
The verdict
NCT00657891, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
Study Summary
We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood tests will be done in a test tube to see if they react differently before and after treatment. The blood cells will be mixed with to whatever the person is allergic.
Interventions
- DRUG Placebo
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657891
The ClinicalTrials.gov registry entry for NCT00657891 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00657891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657891 about?
NCT00657891 is a clinical study titled "The Effect of Xolair (Omalizumab) on Allergy Blood Cells". We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood tests will be done in a test tube to see if they react differently before and after treatment. The blood cells will be mixed with to whatever the person is allergic.
What is the current status of trial NCT00657891?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2007-03. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00657891?
The interventions under investigation include: Placebo (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00657891?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.